Treatment of Inflammatory Bowel Disease with Biologics

151

Kennedy et al. [^45

]

146 CD, 20 UC; 11 cohort totaling 746 patients (meta-analysis)

Retrospective observational

Observational

CD: younger age at diagnosis (<22 years old)Elevated white cell count > 5.25 × 10

9 /L

Elevated fecal calprotectin (> 50μg/g)

Continued immunomodulator

88% (CD)

CD: 36% (1 year)

Mucosal healing

76% (UC/IBDU)

56% (2 year)UC/IBDU: 42% (1 year)

UC: no predictive factor identified

47% (2 years)Meta-analysisCD: 39% (1 year)

Systematic review, Meta-analysis

UC/IBDU: 35% (1 year)

Torres et al. [^12

]

37 studies

Systematic review

50% (CD/UC), 2 years

Markers of active disease

• 
  

54.7–100% (CD)

Poor prognostic factors including complicated or relapsing disease course

67–100% (UC)

IMM

Immunomodulator,

CD

Crohn’s disease,

UC

ulcerative colitis

10 Cessation offlBiologics: Can It BeflDone?